Quantcast

Latest Eisai Inc. Stories

2014-09-10 08:30:23

WOODCLIFF LAKE, N.J. and SAN DIEGO, Sept. 10, 2014 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that data from the Phase 3 clinical trial program for BELVIQ(® )(lorcaserin HCl) CIV will be presented at the American Society of Bariatric Physicians' (ASBP) 64(th) Annual Obesity & Associated Conditions Symposium taking place September 10-13, 2014, in Austin, Texas. "These data presentations continue to support Eisai's efforts to foster a greater...

2014-09-03 08:33:04

WOODCLIFF LAKE, N.J., Sept. 3, 2014 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced it has entered into an agreement with Concordia Pharmaceuticals Inc. ("Concordia"), a subsidiary of Concordia Healthcare Corp., to purchase Eisai's U.S. and Puerto Rican commercialization and distribution rights to Zonegran. As part of the deal terms, Eisai will receive full payment from Concordia upon closing. In addition, Eisai and Concordia are...

2014-08-29 12:24:42

PISCATAWAY, N.J., Aug. 29, 2014 /PRNewswire/ -- InnoPharma, Inc. today announced the approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for decitabine for injection, a generic version of Eisai Inc.'s DACOGEN®. InnoPharma developed the generic formulation of decitabine for injection and entered into an agreement with Sandoz, Inc., pursuant to which Sandoz will sell, market and distribute decitabine for injection in the United...

2014-07-30 08:32:46

WOODCLIFF LAKE, N.J. and SAN DIEGO, July 30, 2014 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that an article based on post-hoc analyses from the three pivotal Phase 3 trials of lorcaserin entitled, "Early Weight Loss While on Lorcaserin, Diet, and Exercise as a Predictor of Week 52 Weight-Loss Outcomes," was recently published in the online issue of Obesity, the official peer reviewed journal of The Obesity Society. The objective of these...

2014-07-29 08:32:10

-- 2014 Nomination follows Previous Nomination in 2013 -- WOODCLIFF LAKE, N.J. and SAN DIEGO, July 29, 2014 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that BELVIQ(®) (lorcaserin HCl) has been nominated by the Galien Foundation and Awards Committee for the 2014 Prix Galien USA Award in the Best Pharmaceutical Agent category. BELVIQ was previously nominated for this award in 2013. "Eisai's commitment to patient care is the driving force behind our...

2014-07-10 08:27:50

-- Sales Force Increased to Approximately 600 Sales Specialists -- SAN DIEGO, July 10, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported that Eisai Inc. has completed its planned increase of more than 200 new contract sales representatives in its Metabolic Business Unit, increasing the sales force for BELVIQ® by 50% to approximately 600. Eisai expects this expansion of the sales force will enable them to increase their reach to approximately 92,000 physicians in...

2014-07-10 08:27:07

LUGANO, Switzerland, July 10, 2014 /PRNewswire/ -- Helsinn Group, the company focused on building quality cancer care, today announces that the complete results of the three Phase 2/3 pivotal trials for the investigational oral fixed-dose combination capsule of netupitant 300 mg + oral palonosetron 0.50 mg (NEPA), which is licensed to Eisai Inc. in the United States, have been published, together with an accompanying editorial, in the July issue of Annals of Oncology....

2014-07-07 16:24:29

THE WOODLANDS, Texas, July 7, 2014 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Lonnel Coats has been appointed president and chief executive officer effective July 7, 2014. Mr. Coats most recently served as president and chief executive officer of Eisai Inc., the United States subsidiary of Eisai Co., Ltd. Mr. Coats joins Lexicon after 18 years of senior management experience with Eisai. As president and chief executive officer at Eisai, he...

2014-06-26 08:27:36

WOODCLIFF LAKE, N.J. and LUGANO, Switzerland, June 26, 2014 /PRNewswire/ -- Eisai Inc. and Helsinn Group announced today that several abstracts highlighting data analyses of NEPA, an investigational oral fixed-dose combination of netupitant and palonosetron being evaluated for the prevention of chemotherapy-induced nausea and vomiting (CINV), will be presented at the International Symposium on Supportive Care in Cancer. The Multinational Association of Supportive Care in...

2014-06-23 12:29:17

Those Who Take Steps Report Greater Satisfaction with Weight Loss Medications and Surgical Procedures WOODCLIFF LAKE, N.J., June 23, 2014 /PRNewswire/ -- An analysis of data from the 2012 U.S. National Health and Wellness Survey showed that the majority of those affected by obesity are not taking steps to lose weight (58.4%). The analysis of more than 71,157 respondents, including approximately 23,000 adults with obesity, was conducted by Eisai Inc. and Kantar Health and results were...


Word of the Day
cruet
  • A vial or small glass bottle, especially one for holding vinegar, oil, etc.; a caster for liquids.
This word is Middle English in origin, and ultimately comes from the Old French, diminutive of 'crue,' flask.
Related